HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Helander, A. Articles by Freeze, H. H. Search for Related Content PubMed PubMed Citation Articles by Helander, A. Articles by Freeze, H. H. Related Collections Molecular Diagnostics and Genetics Proteomics and Protein Markers Endocrinology and Metabolism

Testing for Congenital Disorders of Glycosylation by HPLC Measurement of Serum Transferrin Glycoforms

¹ Department of Clinical Neuroscience, Karolinska Institutet and University Hospital, Stockholm, Sweden² Glycobiology and Carbohydrate Chemistry Program, The Burnham Institute, La Jolla, CA

^aaddress correspondence to this author at: Alcohol Laboratory, L7:03, Karolinska University Hospital, SE-171 76 Stockholm, Sweden; fax 46-8-51771532, e-mail Anders.Helander@cns.ki.se

The first 300 words of the full text of this article appear below.

Congenital disorders of glycosylation (CDG), formerly named carbohydrate-deficient glycoprotein syndrome, are rare hereditary disorders caused by mutations in the genes coding for enzymes involved in the biosynthesis of glycoproteins and other glycoconjugates (1). The clinical characteristics are variable, but often include psychomotor, growth, and mental retardation from early childhood. CDG are the result of defects in the assembly and transfer (type I) or processing (type II) of the glycan moieties, and as a result, the carbohydrate chains are either completely missing (type I) or structurally abnormal (type II). CDG-Ia is the most frequent subtype, with 500 patients reported, whereas <100 patients have been diagnosed with types Ib–Ik and only 10 with type II (IIa–IId) (1)(2)(3)(4)(5). However, it is assumed that the limited awareness of CDG, together with their variable and unspecific clinical symptoms, contribute to underdiagnosis of these disorders (6)(7)(8).

Another reason for underdiagnosis could be that methods for CDG testing are not generally available in clinical laboratories. Testing for CDG focuses mainly on the abnormal pattern of N-linked glycans of serum transferrin. The type I pattern is characterized by an increase of transferrin glycoforms missing one or both of the entire biantennary N-glycans (9)(10) (traditionally named disialo- and asialotransferrin, respectively, based on the number of terminal sialic acid residues), whereas type II is characterized by increased trisialo- and monosialotransferrin, indicating the presence of truncated glycans (11)(12)(13). A variety of laboratory techniques have been evaluated for this purpose, with isoelectric focusing being the most common and serving as the reference procedure to date. A sensitive HPLC method is widely used for detection of alcohol-induced changes in serum transferrin glycoforms [i.e., carbohydrate-deficient transferrin . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				J. P. Bergstrom and A. Helander Clinical Characteristics of Carbohydrate-Deficient Transferrin (%Disialotransferrin) Measured by HPLC: Sensitivity, Specificity, Gender Effects, and Relationship with other Alcohol Biomarkers Alcohol Alcohol., April 24, 2008; (2008) agn017v2. [Abstract] [Full Text] [PDF]

				P. R. Selvin, T. Lougheed, M. Tonks Hoffman, H. Park, H. Balci, B. H. Blehm, and E. Toprak Fluorescence Imaging with One-Nanometer Accuracy (FIONA) of Cy3-DNA under Deoxygenation Conditions CSH Protocols, October 1, 2007; 2007(20): pdb.prot4868 - pdb.prot4868. [Abstract] [Full Text]

				R. K.T. Kam, T. C.W. Poon, H. L.Y. Chan, N. Wong, A. Y. Hui, and J. J.Y. Sung High-Throughput Quantitative Profiling of Serum N-Glycome by MALDI-TOF Mass Spectrometry and N-Glycomic Fingerprint of Liver Fibrosis Clin. Chem., July 1, 2007; 53(7): 1254 - 1263. [Abstract] [Full Text] [PDF]

				J. R. Delanghe, A. Helander, J. P.M. Wielders, J. M. Pekelharing, H. J. Roth, F. Schellenberg, C. Born, E. Yagmur, W. Gentzer, and H. Althaus Development and Multicenter Evaluation of the N Latex CDT Direct Immunonephelometric Assay for Serum Carbohydrate-Deficient Transferrin Clin. Chem., June 1, 2007; 53(6): 1115 - 1121. [Abstract] [Full Text] [PDF]

				A. M. Ostrow, H. Freeze, and J. Rychik Protein-Losing Enteropathy After Fontan Operation: Investigations Into Possible Pathophysiologic Mechanisms Ann. Thorac. Surg., August 1, 2006; 82(2): 695 - 700. [Abstract] [Full Text] [PDF]

				H. A. Carchon, C. Nsibu Ndosimao, S. Van Aerschot, and J. Jaeken Use of serum on guthrie cards in screening for congenital disorders of glycosylation. Clin. Chem., April 1, 2006; 52(4): 774 - 775. [Full Text] [PDF]

				A. Helander, J. P.M. Wielders, R. te Stroet, and J. P. Bergstrom Comparison of HPLC and Capillary Electrophoresis for Confirmatory Testing of the Alcohol Misuse Marker Carbohydrate-Deficient Transferrin Clin. Chem., August 1, 2005; 51(8): 1528 - 1531. [Full Text] [PDF]